<DOC>
	<DOCNO>NCT01522183</DOCNO>
	<brief_summary>Post-marketing safety data patient treat untreated eculizumab .</brief_summary>
	<brief_title>Atypcial Hemolytic-Uremic Syndrome ( aHUS ) Registry</brief_title>
	<detailed_description>The study capture post-marketing safety data patient treat eculizumab . Additionally , study collect information progression disease patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>Male female patient age , include minor , diagnose aHUS Able give write informed consent . Patient patient 's parent/legal guardian must willing able give write informed consent patient ( minor ) must willing give write informed assent [ applicable determined central Institutional Review Boards/Independent Ethics Committees ( IRB/IEC ) ] . ADAMTS13 &gt; 5 % , perform . Hemolytic Uremic Syndrome ( HUS ) due Shiga Toxin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atypical Hemolytic-Uremic Syndrome</keyword>
	<keyword>aHUS</keyword>
	<keyword>Thrombotic Microangiopathy</keyword>
	<keyword>TMA</keyword>
</DOC>